The disconnect is becoming too big to ignore.Everything you...

The disconnect is becoming too big to ignore.

Everything you listed is valid. The science, the data, the people. On paper it all looks like a biotech dream. But if after all that, the market is still shrugging, you have to ask, what are we not seeing?

There are only a few explanations:

1. Poor execution at the top. Great science does not survive bad strategy. If PH and co. are not trusted by the big players in pharma to deliver commercially, that is a problem no amount of clinical promise can fix.

2. No institutional confidence. Retail might be the only ones still believing. Institutions are not touching this, which tells me they have either seen enough to pass or never saw enough to begin with. Either way, not a good sign.

3. Spending problem. You can't keep blowing through cash and raising more at rock-bottom prices, then act surprised when confidence tanks. It just shows there’s no clear plan to actually make money or get bought out.

4. Unclear Communication. If this is such a medical miracle, where is the media hype? Where are the licensing deals? Where are the partnerships that actually shift the share price, not just pad out ASX announcements?

Maybe it is time to stop hoping for external validation and start demanding internal accountability. Something does not add up, and it is not our maths that is the problem.

If the science is doing its job, maybe it's time the board started doing theirs!!!!